As of 2026-09-20, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (101.07) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.51 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -796.6%.
The range of the Relative Valuation is (97.57) - (99.91) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 29.3x - 38.2x | 33.8x |
| Forward P/E multiples | 23.9x - 30.0x | 27.0x |
| Fair Price | (97.57) - (99.91) | (101.07) |
| Upside | -772.5% - -788.5% | -796.6% |
| Date | P/E |
| 2026-09-18 | -4.36 |
| 2026-09-17 | -4.35 |
| 2026-09-16 | -3.87 |
| 2026-09-15 | -3.92 |
| 2026-09-14 | -4.09 |
| 2026-09-11 | -4.29 |
| 2026-09-10 | -4.32 |
| 2026-09-09 | -4.30 |
| 2026-09-08 | -4.47 |
| 2026-09-04 | -4.59 |
| 2026-09-03 | -4.46 |
| 2026-09-02 | -7.97 |
| 2026-09-01 | -7.75 |
| 2026-08-31 | -7.57 |
| 2026-08-28 | -7.69 |
| 2026-08-27 | -7.89 |
| 2026-08-26 | -7.94 |
| 2026-08-25 | -7.95 |
| 2026-08-24 | -7.72 |
| 2026-08-21 | -7.76 |
| 2026-08-20 | -7.60 |
| 2026-08-19 | -7.88 |
| 2026-08-18 | -7.65 |
| 2026-08-17 | -7.85 |
| 2026-08-14 | -7.95 |
| 2026-08-13 | -7.92 |
| 2026-08-12 | -8.07 |
| 2026-08-11 | -8.10 |
| 2026-08-10 | -8.05 |
| 2026-08-07 | -7.78 |
| 2026-08-06 | -7.75 |
| 2026-08-05 | -7.49 |
| 2026-08-04 | -7.75 |
| 2026-08-03 | -7.51 |
| 2026-07-31 | -7.48 |
| 2026-07-30 | -7.82 |
| 2026-07-29 | -7.51 |
| 2026-07-28 | -7.80 |
| 2026-07-27 | -8.07 |
| 2026-07-24 | -8.08 |
| 2026-07-23 | -8.11 |
| 2026-07-22 | -8.30 |
| 2026-07-21 | -8.59 |
| 2026-07-20 | -8.57 |
| 2026-07-17 | -8.79 |
| 2026-07-16 | -9.07 |
| 2026-07-15 | -9.52 |
| 2026-07-14 | -9.62 |
| 2026-07-13 | -9.98 |
| 2026-07-10 | -10.16 |